Background Metabolic-associated steatotic liver disease (MASLD) is a prevalent chronic liver disease affecting approximately ...

The BMP8A Fibrosis Score (BFS) offers improved accuracy over existing noninvasive scoring systems for identifying advanced liver fibrosis in MASH patients. BFS eliminates grey-zone results, providing ...

Liver fibrosis may be diagnosed and staged — no fibrosis (stage F0), mild fibrosis (F1), significant fibrosis (F2), advanced fibrosis (F3), and cirrhosis (F4) — with the use of clinical parameters and ...

Blood-based biomarkers and imaging measures may help monitor MASH disease activity, potentially reducing reliance on liver biopsies. Semaglutide treatment showed significant improvements in liver ...

This study investigates the association between liver fibrosis and diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes mellitus ...

New research shows an AI-driven liquid biopsy analyzing genome-wide cfDNA fragment patterns can detect early liver fibrosis & cirrhosis and may signal broader chronic disease burden.

Researchers at National Jewish Health have shown that subtle increases in lung scarring, detected by an artificial intelligence-based tool on CT scans taken one year apart, are associated with disease ...